| Literature DB >> 28982267 |
Stuart A Scott1,2,3, Aniwaa Owusu Obeng3,4, Mariana R Botton1,2, Yao Yang1,2,5, Erick R Scott1,2,5, Stephen B Ellis3, Richard Wallsten2, Tom Kaszemacher3, Xiang Zhou1,2,5, Rong Chen1,2,5, Paola Nicoletti1,2, Hetanshi Naik1, Eimear E Kenny1,3,5, Aida Vega6, Eva Waite6, George A Diaz1,2, Joel Dudley1,5,7, Jonathan L Halperin8, Lisa Edelmann1,2, Andrew Kasarskis1,5, Jean-Sébastien Hulot9,10, Inga Peter1,3, Erwin P Bottinger3,11, Kurt Hirschhorn1, Pamela Sklar1,5,12, Judy H Cho1,3,13, Robert J Desnick1,2, Eric E Schadt1,2,5.
Abstract
For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.Keywords: Icahn School of Medicine at Mount Sinai; clinical implementation; discovery; education; genetic testing; pharmacogenetics; pharmacogenomics
Mesh：
Year: 2017 PMID： 28982267 PMCID： PMC5694020 DOI： 10.2217/pgs-2017-0137
Source DB: PubMed Journal: Pharmacogenomics ISSN： 1462-2416 Impact factor: 2.533